in this issue
People & Business :: Companies
AstraZeneca’s MedImmune Bid Queried
1:17 PM MDT | July 25, 2007 | Chemical Week Editorial Staff
Shareholders at AstraZeneca’s annual meeting last week raised concerns about the firm’s recent $58/share offer to purchase biotechnology firm MedImmune (Gaithersburg, MD). AstraZeneca’s offer values MedImmune at $15.6 billion and represents a 21% premium over MedImmune’s closing share price on April 20, three days before the bid was announced. Shareholders at the meeting questioned whether the proposed deal is “an act of desperation.” AstraZeneca has been hit by a string of drug candidate failures of late and these may have...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee